View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 21, 2020updated 12 Jul 2022 11:39am

Alzheon secures NIA grant for Alzheimer’s disease trial

Alzheon has received a $47m five-year grant from the US National Institute on Aging (NIA) to conduct a Phase III clinical trial of ALZ-801 as an oral treatment for Alzheimer’s disease.

Alzheon has received a $47m five-year grant from the US National Institute on Aging (NIA) to conduct a Phase III clinical trial of ALZ-801 as an oral treatment for Alzheimer’s disease.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

ALZ-801 is designed to inhibit the formation of neurotoxic soluble amyloid oligomers. It is a brain-penetrant, small molecule prodrug of the active agent tramiprosate.

The Phase III trial will involve early Alzheimer’s patients with two copies of the apolipoprotein e4 allele (APOE4/4).

This patient population is known to be at a higher risk of rapid disease progression and could be responsive to agents targeting pathogenic amyloid oligomers.

Alzheon said that the trial will assess the drug candidate in 300 patients, who will be given 265mg tablets of ALZ-801 or a matching placebo twice daily over 18 months.

The primary clinical outcome is cognitive endpoint on Alzheimer’s Disease Assessment Scale–cognitive subscale (ADAS-cog). The trial will also track functional, behavioural, and global clinical endpoints.

Biomarker assessments will include plasma and cerebrospinal fluid (CSF) measures of core disease pathologies and neurodegeneration, and neuroinflammatory markers.

Imaging biomarkers will assess measurements of hippocampal volume and cortical thickness. The study is expected to launch in the first quarter of next year.

Alzheon chief medical officer Susan Abushakra said: “We are applying precision medicine by targeting patients who can be readily diagnosed, who develop the disease earlier when they are less likely to have comorbidities, and who are likely to benefit from the treatment.

“We are integrating advanced fluid biomarkers into Phase III programme to increase our understanding of the effects of ALZ-801 treatment on the course of the disease.”

The company plans to expand the evaluation of ALZ-801 in prevention trials in healthy participants with high Alzheimer’s risk, and in APOE4 heterozygotes with one copy of the APOE4 gene.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena